Rallybio (Rallybio) EBIT : $-78.93 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Rallybio EBIT?

Rallybio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-21.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-78.93 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rallybio's annualized ROC % for the quarter that ended in Dec. 2023 was -1,660.89%. Rallybio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5,422.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rallybio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 240.22%.

Rallybio EBIT Historical Data

The historical data trend for Rallybio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio EBIT Chart

Rallybio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-17.42

-24.89

-45.50

-67.88

-78.93

Rallybio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial												-17.09	-18.37	-20.08	-19.36	-21.11

Competitive Comparison of Rallybio's EBIT

For the Biotechnology subindustry, Rallybio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rallybio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rallybio's EV-to-EBIT falls into.

Rallybio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.93 Mil.

Rallybio (NAS:RLYB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rallybio's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-84.448 * ( 1 - 0% )	/	( (5.953	+	4.216)	/ 2 )
=	-84.448	/	5.0845
=	-1,660.89 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	133.194	-	5.857	-	( 121.384	-	max(0, 9.402	-	132.422	+	121.384	))
=	5.953

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	115.62	-	5.878	-	( 109.929	-	max(0, 9.263	-	114.789	+	109.929	))
=	4.216

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Rallybio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-84.448	/	( ( (0.67 + max(1.853, 0))	+	(0.592 + max(-4.184, 0)) )	/	2 )
=	-84.448	/	( ( 2.523	+	0.592 )	/	2 )
=	-84.448	/	1.5575
=	-5,422.02 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	11.038)	-	(5.857	+	0	+	3.328)
=	1.853

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.86)	-	(5.878	+	0	+	3.166)
=	-4.184

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Rallybio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-78.932	/	-32.858
	=	240.22 %

Rallybio EBIT Related Terms

Thank you for viewing the detailed overview of Rallybio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Rallybio (Rallybio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

234 Church Street, Suite 1020, New Haven, CT, USA, 06510

Website

https://www.rallybio.com

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Executives

5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber	officer: See Remarks	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu	director	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash	director	C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510